TScan Reprioritizes Around In Vivo TCR-T
TScan is cutting approximately 75% of its workforce, eliminating internal manufacturing and pausing further Phase III ALLOHA-2 enrollment because it lacks sufficient capital to complete the study. Resources will shift to preclinical in-vivo-engineered TCR-T…
